

Full Length Research paper

Vitamin B complex and homocysteine status and Cognitive impairment in the elderly among Indian population

Basheer, M. P.^{1,3,4*}, Soopy, K.², Pradeep Kumar, K. M.², Sreekumaran, E.³ and Ramakrishna, T.³

¹MES Medical College, Kerala, India.

²Govt. Medical College Calicut, Kerala, India.

³Department of Life Sciences, University of Calicut, Kerala, India.

⁴Al Azhar Medical College, India.

Received 21 May, 2015; Accepted 10 November, 2016

Vitamins B complex and homocysteine has been given much attention as preventive factors against cognitive decline and dementia. Hyper homocysteinaemia has been suggested as a cause or mechanism in the development of Alzheimer's disease and other forms of dementia. The present study is designed to know the role of vitamin B complex and homocysteine and its relation with cognition, using biological samples. A total of 337 subjects with a mean age of 49 years participated in the cross sectional study from different parts of Kerala state in India. Participants were administered a series of neuropsychological test batteries with major emphasis on 7-min screen test. All test procedures were administered by standard protocol after a written consent was obtained from the participating subjects. Analysis of vitamin B complex and homocysteine was done, using serum samples and the data obtained was then statistically analyzed using statistical package for social sciences (SPSS) software version 17. Vitamin B₆ and B₉ were found to be significantly related to the cognitive score ($P < 0.001$, $p < 0.003$, respectively). Independent sample test showed a highly significant change with a p value < 0.048 and < 0.019 of vitamin B₁₂ and homocysteine, respectively. The results of our study give us an insight that Vitamin B complex and homocysteine may be closely associated with cognitive function in elderly population. But further studies on a larger population is required to come out with a definite conclusion.

Key words: Cognition, vitamin B₆, folic acid, vitamin B12, homocysteine, dementia.

INTRODUCTION

Vitamins B complex (especially, folate, vitamins B₁₂ and B₆) has been given much attention as preventive factors against cognitive decline and dementia (Kuo et al., 2005;

Morris et al., 2006b; Schneider et al., 2006; Reynolds, 2006; Sachdev, 2005; Troen and Rosenberg, 2005; Luchsinger et al., 2007a). The primary theoretical basis

*Corresponding author. E-mail: drbasheermp@gmail.com. Tel: 00291-7374854, 0091-8547161253.

for this argument rests on the known relations of folate, vitamin B₁₂ and vitamin B₆ as co-factors in the methylation of homocysteine (Hcy), and the importance of deficiencies in these nutrients to increased Hcy concentration (Carmel, 2000; Stabler, 2003). Supra physiological levels of Hcy are neurotoxic in cell culture and *in vivo* mouse models, suggesting that Hcy toxicity may have a direct effect on cognitive decline. Numerous studies in recent years have investigated the role of Hcy as a cause of brain damage (Pacheco-Quinto et al., 2006; Fuso et al., 2005; Ho et al., 2003; Seshadri and wolf, 2003) and neurotoxic effects of Hcy can be blocked by folate, glutamate receptor antagonists or various antioxidants (Olney et al., 1987; Kim et al., 1987). Hyper homocysteinaemia has been suggested as a cause or mechanism in the development of Alzheimer's disease and other forms of dementia. Supplementation with B vitamins including vitamin B₆ has been shown to reduce blood homocysteine levels (Malouf and Grimley, 2003).

High folate intake was associated with reduced risk of developing AD in the Baltimore Longitudinal Study of Aging (Corrada et al., 2005), but there was no association with vitamin supplement and/or food intake of folate in the Chicago Health and Aging Project (CHAP) study (Morris et al., 2006a). In both studies, no association was found with total intake of vitamins B₁₂ or B₆. Earlier studies relating homocysteine levels to dementia risk have shown inconsistent results (Ariogul et al., 2005; Gunstad et al., 2006; Haan et al., 2007; Mooijaart et al., 2005; Seshadri, 2006). Moreover, there are a limited number of prospective cohort studies on B vitamins and dementia, and the findings have not been consistent. Very few prospective studies examined the levels of B vitamins and Hcy in relation to incidence of dementia (Luchsinger et al., 2004; Corrada et al., 2005; Ravaglia et al., 2005; Morris et al., 2006b; Luchsinger et al., 2007b; Wald et al., 2011).

Some of these studies that used serum measures found a significantly greater risk of developing AD among persons who had low levels of either vitamin B₁₂ (<150 pmol/L) or folate (14 µmol/L) and was associated with almost double the risk of dementia and AD (Seshadri et al., 2002). There are a lot of discrepancies existing on whether Vitamin B supplement can reduce cognitive impairment by decreasing serum homocysteine level (Wald et al., 2010; Kwok et al., 2011; De Jager et al., 2012; Ford and Almeida, 2012; Douaud et al., 2013).

Our study was aimed to identify the role of vitamin B complex and homocysteine level in serum of normal and cognitively impaired Indian population based on 7-min screen test and other neuropsychological tests.

MATERIALS AND METHODS

Participants

Participants were a part of a cross-sectional study of

Calicut University Project to Investigate Memory and Ageing (CUPTIMA), as adapted and standardized for Malayalam speaking population (De Jager et al., 2008). We administered a series of neuropsychological test batteries (7-min Screen Test, CERAD Memory function test, Trail Making Test-TMT, Global versus Local attention task test, Handedness test, Mini Mental State Examination-MMSE and Geriatric Depression Scale-GDS) to 337 healthy individuals belonging to various places of Kerala state of South India, especially Trissur, Palakad, Malappuram and Kozhikode districts, for about a 7 year period. All of them except three were left handed and none of them were inarticulate. Only participants who were having no history of stroke, head trauma, neurological disease, psychological illness, or any other known present illness and those who know Malayalam or English or both were chosen as participants. Individual participants were subjected to different test batteries. Participants ranged from ages of 20 to 84 years with a mean age of 49 years, having educational backgrounds ranging from four to twenty years. Participants were grouped into categories based on their sex, age and education. All test procedures were explained and a written consent was obtained from them. All the tests were administered based on standard protocol (Oxford Project to Investigate Memory and Ageing [OPTIMA], Cambridge Mental Disorders of the Elderly Examination [CAMDEX] and CUPTIMA).

All the study participants had given their informed written consent and study was approved by Human ethical committee.

Procedure

The 7-min screen test was developed to assess cognitive impairment especially in dementia prone Alzheimer's disease. Various tests coming under this are orientation test, memory test, clock drawing test and verbal fluency test. The scores obtained from all the aforementioned tests were then analysed using the scoring calculator, to find out the probability of dementia related problems (Solomon et al., 1998). Vitamin B₆ was estimated by (ID-Vit® Vitamin B₆ Immundiagnostik AG Stubenwald-Allee 8a 64625 Bensheim, Germany), folic acid assayed by Roche Elecsys 2010 immunoassay analyzer, Vitamin B₁₂ assayed by ADVIA Centaur (Bayer diagnostic/Seimen Healthcare Diagnostics) and homocysteine assayed by ADVIA Centaur (Bayer diagnostic/Seimen Healthcare Diagnostics).

Statistical analysis

The data of biochemical test parameters was analysed with SPSS software version 17. Statistical tests were conducted, which include analysis of variance (ANOVA), Independent sample test and Pearson correlation.

RESULT

The 7-min screen test was administered in all the age groups and found an increasing trend in the score as age advanced (Table 1). Orientation score in younger age group was compared with older age groups. A statistically significant difference was found between younger age group (20 to 29) and other groups ($p < 0.05$). One way ANOVA was conducted between the groups and within the groups and a mean square value of 52.847 and 0.518 was obtained, respectively with a highly significant p value (< 0.001). The score in males was 1.4 ± 1.14 and

Table 1 Mean 7-Minute screen test score in different age groups, education category and sex of participants.

Parameter	Orientation				Memory		Clock drawing		Verbal fluency	
	Age	N	M	SD	M	SD	M	SD	M	SD
Age group	20-29	60	0.35	0.481	15.6	0.527	6.37	0.736	23.15	2.441
	30-39	58	0.71	0.726	15.34	0.637	6.28	0.951	22.93	2.937
	40-49	57	1.07	0.799	15.09	0.714	6.02	0.896	22.35	2.949
	50-59	52	1.56	0.873	14.92	0.652	5.75	1.118	21.35	2.424
	60-60	48	2.17	0.859	14.73	0.644	5.33	1.294	20.00	2.642
	70-79	43	2.81	0.588	14.28	0.908	4.51	1.162	17.60	2.331
	≥80	19	3.74	0.452	12.63	0.895	3.47	0.513	13.63	1.342
	Total	337	1.48	1.205	14.91	0.971	5.65	1.273	21.01	3.618
Educational group	Primary	129	2.02	1.104	14.52	0.985	5.17	1.347	19.47	3.300
	Secondary	144	1.23	1.163	15.06	0.937	5.85	1.202	21.38	3.363
	Tertiary	64	0.98	1.105	15.34	0.718	6.17	0.918	23.28	3.402
	Total	337	1.48	1.205	14.91	0.971	5.65	1.273	21.01	3.618
Sex group	Male	174	1.40	1.142	15.10	0.802	5.78	1.245	21.48	3.523
	Female	163	1.58	1.266	14.70	1.089	5.52	1.293	20.50	3.661

for females, it was 1.58 ± 1.266 . No statistically significant difference was observed between the scores of males and females ($p=0.171$). It was also found that when the education level increased the orientation score decreased. A statistically significant difference was observed between the highly educated and the uneducated in the orientation test score ($p<0.001$). In primary educated group, the value was 2.02 ± 1.104 , in the secondary educated group it was 1.23 ± 1.16 but in the tertiary educated group, it was 0.98 ± 1.11 . The values were statistically highly significant ($p<0.001$).

Memory test was administered in all the age groups and was found to have a decreasing trend in the score as age advanced. Memory test in younger age group (20 to 29) was 15.6 ± 0.527 , and in 80 and above age group, it was 12.63 ± 0.90 . A statistically significant difference was found between younger and older age groups ($p<0.001$). Mean square value from one way ANOVA revealed a highly significant change ($p<0.001$) between the groups and within the groups (26.442 and 0.48, respectively). The score in males and females were compared and the values were 15.1 ± 0.802 for males and 14.7 ± 1.089 for females. A statistically significant difference was observed between the scores of males and females ($p<0.001$). A statistically significant difference was observed between the highly educated participants and the uneducated in the memory test score ($p<0.001$). In the primary educated group, the value was 14.52 ± 0.99 , in the secondary educated group, it was 15.06 ± 0.94 , but in the tertiary educated group, it was 15.34 ± 0.72 . Statistically the values were highly significant ($p<0.001$).

The clock drawing test was administered in all the participants and seen to be correlated. The result was showing a decreasing trend as age advanced. In the younger age group (20 to 29) the value was 6.37 ± 0.74 ;

however the value in subjects above 80 years was 3.47 ± 0.51 . One way ANOVA revealed a statistically significant difference ($p<0.001$) between the groups and within the groups with a mean square value of 35.38 and 1.007. The score was found to be increased as the education level advanced. The score in males were 5.78 ± 1.245 and for females it was 5.52 ± 1.293 . A statistically significant difference was observed between the score in males and females ($p=0.06$). A statistically significant difference was observed between the highly educated participants and the uneducated in the clock drawing test score ($p<0.001$). In the primary educated group, the value was 5.17 ± 1.35 , in the secondary educated group, it was 5.85 ± 1.20 , but in the tertiary educated group it was 6.17 ± 0.92 . Statistically the values were highly significant ($p<0.001$).

Verbal fluency (Semantic category) test was administered in all the participants and was found to be having a decreasing trend in the score as age advanced. Verbal fluency test in younger age group was compared with all other groups. A statistically significant difference was found between younger age and the older age groups ($p<0.001$). Mean square value between the groups and within the groups was 363.194 and 6.724. It was also found that as the education level increased the verbal fluency score also increased. A statistically significant difference was observed between the subjects with higher education level and those with lower education level. In subjects who completed tertiary level of education, the score was found to be higher than the primary educated group. The scores in the tertiary educated group and uneducated primary group were compared and found to be statistically significant ($p<0.001$), which shows that there is cognitive impairment in uneducated and elderly participants. The verbal

Table 2 Dementia probability in different age groups (descriptive).

		N	Mean age	SD	95 % Confidence interval for mean	
					Lower bound	Upper bound
Dementia probability	HI	43	75.81	6.929	73.68	77.95
	LO	286	44.33	16.564	42.4	46.26
	RE	8	67.75	5.12	63.47	72.03
	Total	337	48.91	18.926	46.88	50.93

Table 3 Dementia probability in different education category and sex (crosstab).

		Educational level				Sex		
		Primary	Secondary	Tertiary	Total	Male	Female	Total
Dementia characteristic of Alzheimer's disease	HI	27	13	3	43	17	26	43
		62.80%	30.20%	7.00%	100.00%	39.5%	60.5%	100%
	LO	97	129	60	286	153	133	286
		33.90%	45.10%	21.00%	100.00%	53.5%	46.5%	100.0%
	RE	5	2	1	8	4	4	8
		62.50%	25.00%	12.50%	100.00%	50.0%	50.0%	100%
Total		129	144	64	337	174	163	337
		38.30%	42.70%	19.00%	100.00 %	51.6%	48.4%	100.0%

fluency test in males and females were also compared. The score in males and females were 21.48 ± 3.523 and 20.5 ± 3.661 , respectively. Statistically significant difference was observed between the scores in males and females ($p < 0.001$).

Based on the 7-min screen test, probability of dementia in the different age groups was also calculated. The participants with 75.81 ± 6.92 age ($n=43$) showed high probability to dementia (HI) than the lower age group 'LO' (44.33 ± 16.56 , $n=286$). A statistically significant difference in dementia probability was observed between the higher and lower age groups ($p < 0.001$) (Table 2), of which eight subjects were re checked (RE). Among HI dementia probability with Alzheimer's characteristics, 39.5 % were males and 60.5 % were females. However, we got an interesting finding that as the status of education increased the chances of dementia with characteristics of Alzheimer's disease decreased ($p < 0.001$) (Table 3).

Out of these selected participants for biochemical investigation, 37.5 % belonged to HI group, 37.5 % belonged to LO group and remaining 25% belonged to RE group based on the 7-min screen test. All the participants were well matched for age and sex. A number of cognitive assessment tests were used to evaluate cognitive function in this population and a composite score was created to represent cognitive function/impairment. Descriptive statistics for each biochemical test parameters are presented in Table 4 and 5. Vitamin B₆ was estimated in all the participant

groups. In the LO group, the mean serum vitamin B₆ was 58.86 ± 3.70 and in the HI group it was 35.39 ± 2.87 . One way ANOVA was conducted between the groups and within the groups which showed highly significant changes. Between the groups, the mean square value was 1668.13 with a p-value of < 0.001 . Within the groups the value was 9.88 with a p value of < 0.001 (Table 4 and Figure 1).

Vitamin B₉ (folic acid) was estimated in all the participant groups. In the LO group the mean serum vitamin B₉ was 23.47 ± 6.37 and in the HI group it was 15.20 ± 4.93 . One way ANOVA was conducted between the groups and within the groups which showed a highly significant change. Between the groups the mean square value was 206.21 with a p value of < 0.003 and within the groups the value was 28.95 with a p value of < 0.003 (Table 4 and Figure 2).



Vitamin B₁₂ was estimated in all the participant groups. In the LO group, the mean serum Vitamin B₁₂ was 262.22 ± 72.70 and in the HI group it was 215.00 ± 28.30 . Independent sample test was conducted between the groups and within the groups which showed highly significant changes with a p value of < 0.048 (Table 5 and Figure 3). Homocysteine was estimated in all the participant groups. In the LO group the mean serum Hcy was 12.03 ± 1.78 and in the HI group it was 15.30 ± 4.11 . Independent sample test was conducted between the groups and within the groups, which showed a highly significant change with a p value of < 0.019 . (Table 5 and Figure 4).

Table 4. Mean serum Vitamin B₆ and Vitamin B₉ values (nmol/L) in different categories.

Parameter	N	Vitamin B ₆			Vitamin B ₉		
		Mean	SD	SE	Mean	SD	SE
HI	12	35.392	2.8716	0.829	15.2	4.936	1.425
LO	12	58.867	3.7019	1.069	23.47	6.374	1.84
RE	8	44.9	2.5388	0.898	18.7	4.219	1.492
Total	32	46.572	10.811	1.911	19.18	6.355	1.123

Table 5 Mean serum Vitamin B₁₂ (pmol/L) and Homocysteine (μmol/L) values in different categories.

Parameter		Vitamin B ₁₂			Homocysteine		
		M	SD	SE	M	SD	SE
HI	12	215.002	28.305	8.171	15.3	4.1152	1.1879
LO	12	262.228	72.704	20.99	12.033	1.7824	0.5145

**Figure 1.** Mean serum level of Vitamin B₆ in different categories of participant groups.**Figure 2.** Mean serum level of Vitamin B₉ in different categories of participant groups

DISCUSSION

Micronutrient status can affect cognitive function at all ages. Vitamin deficiencies could influence memory function and might contribute to age-associated cognitive impairment and dementia. Vitamins are required for proper development of brain (Ramakrishna, 1999). Epidemiological studies indicate that poor vitamin B₆ status is common among older people. Hyper homocysteinaemia has been suggested as a cause or mechanism in the development of Alzheimer's disease and other forms of dementia. The prevalence of Alzheimer's disease is expected to quadruple by the year 2047. Delaying its onset would decrease its burden (Brookmeyer et al., 1998). Around one in six elderly

people (70+) has mild cognitive impairment (MCI) and experience problems with memory, language or other mental functions, but not to a degree that interferes with their daily life. The B vitamins such as folic acid, vitamin B₆ and vitamin B₁₂ are known to control levels of homocysteine in the blood and high levels of Hcy are associated with an increased Alzheimer's risk (Smith et al., 2010).

Homocysteine levels greater than 1.9 mg/L (14 μmol/L) doubled the risk of AD in the Framingham study (Seshadri et al., 2002) but there was no relation between the plasma levels of folate and vitamins B₆ and B₁₂ and the risk of AD. Our study also found that homocysteine level is higher than 14 μmol/L in HI dementia probability




Figure 3. Mean serum level of Vitamin B₁₂ in different categories of participant groups.

with Alzheimer's characteristic population. But in contrast, we have observed that there is close relationship between serum level folate, vitamin B₆ and B₁₂ with HI dementia probability with Alzheimer's characteristics. The elevated homocysteine levels are related to cognitive decline (Elias et al., 2005; Tucker, 2005; Schafer et al., 2005; Wright et al., 2004) and higher dementia risk (Ravaglia et al., 2005). Vitamin B₁₂ supplementation was accompanied by improved language and frontal lobe function test, results in the patients with cognitive impairment. Another study (Douaud et al., 2013) conducted recently revealed that vitamin treatment, by lowering total homocysteine levels markedly reduces gray matter atrophy in regions particularly susceptible to Alzheimer's disease. Our results are consistent with those studies suggesting that higher intake or serum level of folate is related to a lower risk of AD and thereby improve cognitive performance.

Vitamin B₁₂ in addition to its effects on Hcy levels, its deficiency is thought to cause neurological problems by formation of increased methylmalonic acid (MMA) or decreasing the enzyme regenerates methionine from homocysteine. Methionine is needed to make S-adenosyl-methionine (SAMe), which is required for the production of the phospholipids that become a part of the myelin sheath essential for the proper functioning of the nervous system. Demyelination due to B₁₂ deficiency can occur in the brain. When it occurs in the brain, it manifests as cognitive impairment. Further results from an Oxford University study in 2010 appear to suggest that B vitamins can slow mental decline in some elderly people with mild memory problems (mild cognitive impairment). This effect is apparent in participants with high levels of an amino acid, homocysteine, in blood (De Jager et al., 2012).




Figure 4 Mean serum level of homocysteine in different categories of participant groups

Baseline homocysteine levels showed a concentration-response relationship with the subsequent rate of decline in cognitive test scores: the higher the homocysteine, the faster the decline. Raised homocysteine concentrations within the normal range among the elderly strongly relate to the rate of global cognitive decline.

The results of our cross sectional study indicate that there is a strong, graded association between plasma total homocysteine levels and the risk of HI probability dementia of Alzheimer's type. An increment in the plasma homocysteine level of 3 μ mol per liter increased the risk of HI probability dementia of Alzheimer's type. A similar result was found when the single criterion of hyper homocysteinemia (baseline plasma homocysteine, >14 μ mol per liter) was used. The observed association appeared to be independent of age, sex, plasma vitamin B levels and other putative risk factors for dementia and Alzheimer's disease. The relation between elevated plasma homocysteine levels and dementia has been evaluated in other cohort studies (Clarke et al., 1998), and our studies also observed similar findings. In our study population, an elevated homocysteine level at base line was related to a decline in the scores on 7-min screen test and other cognitive tests (data not shown).

Conflict of interest

The authors have not declared any conflict of interest.

REFERENCES

- Ariogul S, Cankurtaran M, Dagli N, Khalil M, Yavuz B (2005). Vitamin B₁₂, folate, homocysteine and dementia: are they really related? *Arch. Gerontol. Geriatr.* 40:139-146.
- Brookmeyer R, Gray S, Kawas C (1998). Projections of Alzheimer's disease in the United States and the public health impact of delaying

- disease onset. *Am. J. Public Health* 88:1337-1342.
- Carmel R (2000). Current concepts in cobalamin deficiency. *Annu. Rev. Med.* 51:357-375.
- Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. (1998). Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer's disease. *Arch. Neurol.* 55:1449-1455.
- Corrada MM, Kawas CH, Hallfrisch J, Muller D, Brookmeyer R (2005). Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging. *Alzheimers Dement.* pp.11-18.
- de Jager CA, Thambisetty M, Praveen KV, Sheeba PD, Ajini KN, Sajeev A, Smitha KK, Rahmathulla LP, Ramakrishna T, Smith AD (2008). Utility of the Malayalam translation of the 7- minute screen for Alzheimer's disease risk in an Indian community. *Neurol. India* 56(2):161-166.
- De Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD (2012). Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. *Int. J. Geriatr. Psychiatr.* 27(6):592-600.
- Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD (2013) Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. *Proc. Natl. Acad. Sci.* 110(23):9523-9528.
- Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Jacques PF, Selhub J, Seshadri S, Au R, Beiser A, Wolf PA (2005). Homocysteine and cognitive performance in the Framingham Offspring Study: age is important. *Am. J. Epidemiol.* 162:644-653.
- Ford AH, Almeida OP (2012) Effect of homocysteine lowering treatment on cognitive function: A systematic review and meta-analysis of randomized controlled trials. *J. Alzheimers Dis.* 29(1):133-149.
- Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S (2005). S-adenosyl-methionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. *Mol. Cell. Neurosci.* 28:195-204.
- Gunstad J, Bausserman L, Paul RH, Tate DF, Hoth K, Poppas A (2006). C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. *J. Clin. Neurosci.* 13:540-546.
- Haan MN, Miller JW, Aiello AE, Whitmer RA, Jagust WJ, Mungas DM (2007). Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. *Am. J. Clin. Nutr.* 85:511-517.
- Ho PI, Ashline D, Dhitavat S, Ortiz D, Collins SC, Shea TB, Rogers E (2003). Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. *Neurobiol. Dis.* 14:32-42.
- Kim JP, Koh JY, Choi DW (1987). L-homocysteate is a potent neurotoxin on cultured cortical neurons. *Brain Res.* 43:103-110.
- Kuo HK, Sorond FA, Chen JH, Hashmi A, Milberg WP, Lipsitz LA (2005). The role of homocysteine in multisystem age-related problems: a systematic review. *J. Gerontol. Med. Sci.* 60A(9):1190-1201.
- Kwok T, Lee J, Law CB, Pan PC, Yung CY, Choi KC, Lam LC (2011). A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. *Clin. Nutr.* 30:297-302.
- Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R (2007a). Relation of higher folate intake to lower risk of Alzheimer's disease in the elderly. *Arch. Neurol.* 64:86-92.
- Luchsinger JA, Tang MX, Miller J, Green R, Mehta PD, Mayeux R (2007b). Relation of plasma homocysteine to plasma amyloid beta levels. *Neurochem. Res.* 32:775-781.
- Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R (2004). Plasma homocysteine levels and risk of Alzheimer disease. *Neurology* 62:1972-1976.
- Malouf R, Grimley Evans J (2003). Vitamin B6 for cognition (Review). *Cochrane Database of Systematic Reviews* 2003, Issue 4. Art. No.:CD004393. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004393/abstract;jsessionid=F4784A6F6C75092D9FCB30FD38940543.f02t03>.
- Mooijart SP, Gussekloo J, Frolich M, Jolles J, Stott DJ, Westendorp RG, de Craen AJ (2005). Homocysteine, vitamin B-12, and folic acid and the risk of cognitive decline in old age: the Leiden 85-Plus study. *Am. J. Clin. Nutr.* 82:866-871.
- Morris MC, Evans DA, Schneider JA, Tangney CC, Bienias JL, Aggarwal NT(2006a). Dietary folate and vitamins B12 and B6 not associated with incident Alzheimer's disease. *J. Alzheimers Dis.* 9:435-443.
- Morris MC, Schneider JA, Tangney CC(2006b). Thoughts on B-vitamins and dementia. *J. Alzheimers Dis.* 9:429-433.
- Olney JW, Price MT, Salles KS, Labruyere J, Ryerson R, Mahan K, Frierdich G, Samson L (1987). L-homocysteic acid: an endogenous excitotoxic ligand of the NMDA receptor. *Brain Res Bull.* 19(5):597-602.
- Pacheco-Quinto J, Rodriguez de Turco, EB DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, Refolo L, Petanceska S, Pappolla MA (2006). Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. *Neurobiol. Dis.* 21:651-656.
- Ramakrishna T (1999). Vitamins and brain development. *Physiol. Res.* 48:175-187.
- Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F (2005). Homocysteine and folate as risk factors for dementia and Alzheimer disease. *Am. J. Clin. Nutr.* 82:636-643.
- Reynolds E (2006). Vitamin B12, folic acid and the nervous system. *Lancet Neurol.* 5:949-960.
- Sachdev PS (2005). Homocysteine and brain atrophy. *Progress Neuro psychopharmacol. Biol. Psychiatr.* 29:1152-1161.
- Schaffer JH, Glass TA, Bolla KI, Mintz M, Jedlicka AE, Schwartz BS (2005). Homocysteine and cognitive function in a population-based study of older adults. *J. Am. Geriatr. Soc.* 53:381-388.
- Schneider JA, Tangney CC, Morris MC (2006). Folic acid and cognition in older persons. *Expert Opin. Drug Saf.* 5:511-522.
- Seshadri S, Wolf PA (2003). Homocysteine and the brain: vascular risk factor or neurotoxin? *Lancet Neurol.* 2(1):11.
- Seshadri S (2006). Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease? *J. Alzheimers Dis.* 9:393-398.
- Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *New England J. Med.* 346:476-483.
- Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H (2010). Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial. *PLoS ONE* 5(9):e122441-10.
- Solomon PR, Hirschhoff A, Kelly B, Relin M, Brush M, DeVeaux RD, Pendlebury WW (1998). A 7 Minute Screening battery highly sensitive to Alzheimer's disease. *Arch. Neurol.* 55(3):349-55.
- Stabler SP (2003). Vitamins, homocysteine and cognition. *Am. J. Clin. Nutr.* 78:3590-360.
- Troen A, Rosenberg I (2005). Homocysteine and cognitive function. *Semin. Vasc. Med.* 5:209-214.
- Tucker KL, Qiao N, Scott T, Rosenberg IH, Spiro AR (2005). High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. *Am. J. Clin. Nutr.* 82:627-635.
- Wald DS, Kasturiratne A, Simmonds M (2010). Effect of folic acid, with or without other B vitamins, on cognitive decline: Meta-analysis of randomized trials. *Am. J. Med.* 123(6):522-527.
- Wald DS, Kasturiratne A, Simmonds M (2011). Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participants. *Alzheimers Dement.* 7(4):412-417.
- Wright CB, Lee HS, Paik MC, Stabler SP, Allen RH, Sacco RL (2004). Total homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan Study. *Neurology* 63(2):254-60.